Proteomics International raises A$3.0 million via a heavily oversubscribed Placement.
Successful capital raising leaves Proteomics well-funded into CY20 and beyond and importantly gives the Company a strong balance sheet for any potential future licensing/partnering discussions around PromarkerD.
